Charles Schwab Investment Management Inc. Has $28.08 Million Stake in LivaNova PLC (NASDAQ:LIVN)

Charles Schwab Investment Management Inc. lessened its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 606,360 shares of the company's stock after selling 15,599 shares during the period. Charles Schwab Investment Management Inc. owned about 1.12% of LivaNova worth $28,081,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. Central Pacific Bank Trust Division grew its stake in LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock valued at $191,000 after acquiring an additional 720 shares in the last quarter. Captrust Financial Advisors acquired a new stake in LivaNova during the third quarter valued at $217,000. Sanctuary Advisors LLC purchased a new position in LivaNova in the third quarter valued at about $219,000. Edgestream Partners L.P. acquired a new position in LivaNova in the 3rd quarter worth about $244,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of LivaNova during the 3rd quarter worth about $292,000. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Stock Performance

Shares of NASDAQ LIVN traded down $0.97 during trading hours on Friday, hitting $39.46. 743,164 shares of the company's stock were exchanged, compared to its average volume of 597,816. The stock has a market capitalization of $2.14 billion, a price-to-earnings ratio of 93.95 and a beta of 1.10. The company's 50-day moving average price is $45.45 and its 200-day moving average price is $48.83. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova PLC has a 1-year low of $36.85 and a 1-year high of $64.48.

Remove Ads

Analysts Set New Price Targets

LIVN has been the subject of several recent research reports. Barclays dropped their price objective on LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a report on Friday, March 7th. Mizuho dropped their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. Stifel Nicolaus reduced their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Needham & Company LLC reissued a "buy" rating and set a $64.00 target price on shares of LivaNova in a research report on Monday. Finally, Wolfe Research lowered LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $61.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.